FDA Approval: MARIPOSA, First-Line Amivantamab plus Lazertinib for EGFR NSCLC
Update: 2024-08-20
Description
Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab..
Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.
Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
